Hengrui Pharma(SH:600276) Ge Long Hui A P P·2025-09-09 09:11Group 1 - Company Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of Heng Rui Medicine (600276.SH), has received approval from the National Medical Products Administration for the market launch of Eicosapentaenoic Acid Ethyl Ester Soft Capsules [1] - Eicosapentaenoic acid (EPA) is a stable ethyl ester of omega-3 fatty acid, which has been shown to reduce the synthesis and/or secretion of very low-density lipoprotein triglycerides (VLDL-TG) in the liver and improve the clearance rate of triglycerides (TG) in circulating VLDL particles [1] - Elevated TG levels are an independent risk factor for increased ischemic cardiovascular events, highlighting the clinical need for a drug that can safely and effectively lower TG levels and the incidence of ischemic cardiovascular events, particularly in combination with statins and with a low incidence of adverse reactions [1] Group 2 - Current medications for lowering TG include fibrates, niacin, and mixed omega-3 polyunsaturated fatty acids, but studies indicate that these drugs do not provide clear benefits in reducing cardiovascular events [1]